Related Experiment Videos
Lithium combined with haloperidol in schizophrenic patients
Y Lerner1, Y Mintzer, M Schestatzky
1Hadassah Medical School, Hebrew University, Doar Na'Shimshon, Israel.
The British Journal of Psychiatry : the Journal of Mental Science
|September 1, 1988
Summary
Adding lithium to haloperidol benefited schizophrenic patients with depression. This treatment augmentation showed effectiveness in patients resistant to neuroleptic medication alone.
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Previous studies suggested lithium augmentation may benefit schizoaffective disorder.
- Schizophrenia treatment often involves antipsychotics like haloperidol.
Purpose of the Study:
- To investigate the efficacy of lithium augmentation in schizophrenic patients with depressive symptoms.
- To determine if lithium benefits patients resistant to haloperidol monotherapy.
Main Methods:
- 36 schizophrenic patients were divided into depressive and non-depressive groups based on BPRS depression scores.
- Patients received either haloperidol plus lithium or haloperidol plus placebo for 8 weeks.
Main Results:
- Schizophrenic patients with higher initial depression scores showed resistance to haloperidol alone.
- The addition of lithium significantly benefited patients in the depressive subgroup.
Conclusions:
- Lithium augmentation is a potentially effective strategy for schizophrenic patients experiencing depressive symptoms.
- This approach may improve outcomes for individuals with treatment-resistant schizophrenia and comorbid depression.